Programa de Biología Sintética, Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, 62210 Cuernavaca, Mexico.
Department of Cell & Systems Biology, University of Toronto, Toronto, Ontario, Canada.
Mol Biol Evol. 2022 Sep 1;39(9). doi: 10.1093/molbev/msac185.
Bacterial adaptation to stressful environments often produces evolutionary constraints whereby increases in resistance are associated with reduced fitness in a different environment. The exploitation of this resistance-cost trade-off has been proposed as the basis of rational antimicrobial treatment strategies designed to limit the evolution of drug resistance in bacterial pathogens. Recent theoretical, laboratory, and clinical studies have shown that fluctuating selection can maintain drug efficacy and even restore drug susceptibility, but can also increase the rate of adaptation and promote cross-resistance to other antibiotics. In this paper, we combine mathematical modeling, experimental evolution, and whole-genome sequencing to follow evolutionary trajectories towards β-lactam resistance under fluctuating selective conditions. Our experimental model system consists of eight populations of Escherichia coli K12 evolving in parallel to a serial dilution protocol designed to dynamically control the strength of selection for resistance. We implemented adaptive ramps with mild and strong selection, resulting in evolved populations with similar levels of resistance, but with different evolutionary dynamics and diverging genotypic profiles. We found that mutations that emerged under strong selection are unstable in the absence of selection, in contrast to resistance mutations previously selected in the mild selection regime that were stably maintained in drug-free environments and positively selected for when antibiotics were reintroduced. Altogether, our population dynamics model and the phenotypic and genomic analysis of the evolved populations show that the rate of resistance adaptation is contingent upon the strength of selection, but also on evolutionary constraints imposed by prior drug exposures.
细菌适应压力环境通常会产生进化限制,即增加抗性与在不同环境中的适应性降低相关。这种抗性成本权衡的利用被提议作为合理抗菌治疗策略的基础,旨在限制细菌病原体中耐药性的进化。最近的理论、实验室和临床研究表明,波动选择可以维持药物疗效,甚至恢复药物敏感性,但也会增加适应性的速度,并促进对其他抗生素的交叉耐药性。在本文中,我们结合数学建模、实验进化和全基因组测序,在波动选择条件下追踪β-内酰胺类抗生素耐药性的进化轨迹。我们的实验模型系统由八个平行进化的大肠杆菌 K12 种群组成,以一种连续稀释方案设计,旨在动态控制耐药性选择的强度。我们实施了温和和强烈选择的适应性斜坡,导致具有相似抗性水平的进化种群,但具有不同的进化动态和不同的基因型特征。我们发现,在没有选择的情况下,强选择下出现的突变是不稳定的,而以前在温和选择条件下选择的抗性突变在无药物环境中稳定维持,并在引入抗生素时被正向选择。总的来说,我们的群体动态模型和进化群体的表型和基因组分析表明,抗性适应性的速度取决于选择的强度,但也取决于先前药物暴露所施加的进化限制。